-
1
المؤلفون: Harry G M Heijerman, Edward F McKone, Damian G Downey, Eva Van Braeckel, Steven M Rowe, Elizabeth Tullis, Marcus A Mall, John J Welter, Bonnie W Ramsey, Charlotte M McKee, Gautham Marigowda, Samuel M Moskowitz, David Waltz, Patrick R Sosnay, Christopher Simard, Neil Ahluwalia, Fengjuan Xuan, Yaohua Zhang, Jennifer L Taylor-Cousar, Karen S McCoy, Karen McCoy, Scott Donaldson, Seth Walker, James Chmiel, Ronald Rubenstein, Deborah K. Froh, Isabel Neuringer, Manu Jain, Kathryn Moffett, Jennifer L. Taylor-Cousar, Bruce Barnett, Gary Mueller, Patrick Flume, Floyd Livingston, Nighat Mehdi, Charlotte Teneback, John Welter, Raksha Jain, Dana Kissner, Kapilkumar Patel, Francisco J. Calimano, Jimmy Johannes, Cori Daines, Thomas Keens, Herschel Scher, Subramanyam Chittivelu, Sudhakar Reddivalam, Ross Carl Klingsberg, Larry G. Johnson, Stijn Verhulst, Patricia Macedo, Damien Downey, Gary Connett, Edward Nash, Nicholas Withers, Timothy Lee, Marleen Bakker, Harry Heijerman, Francois Vermeulen, Christiane Knoop, Elke De Wachter, Renske van der Meer, Petrus Merkus, Christof Majoor
المساهمون: Pulmonology, AII - Inflammatory diseases, Clinical sciences, Physiotherapy, Human Physiology and Anatomy, Pediatrics
المصدر: Lancet, 394(10212), 1940-1948. Elsevier Limited
VX17-445-103 Trial Group 2019, ' Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial ', Lancet, vol. 394, no. 10212, pp. 1940 . https://doi.org/10.1016/S0140-6736(19)32597-8
Lancet
The Lancet, 394(10212), 1940. Elsevier Limitedمصطلحات موضوعية: Male, Indoles, Pyrrolidines, Cystic Fibrosis, Pyridines, Clinical Trial, Phase III, Phases of clinical research, Cystic Fibrosis Transmembrane Conductance Regulator, 030204 cardiovascular system & hematology, Quinolones, Aminophenols, Cystic fibrosis, law.invention, Ivacaftor, chemistry.chemical_compound, 0302 clinical medicine, Randomized controlled trial, law, 030212 general & internal medicine, Pyridines/administration & dosage, Non-U.S. Gov't, Chloride Channel Agonists, Sweat, Child, Chloride Channel Agonists/administration & dosage, Medicine(all), biology, Research Support, Non-U.S. Gov't, Lumacaftor, General Medicine, Indoles/administration & dosage, Clinical Trial, Cystic fibrosis transmembrane conductance regulator, Pyrrolidines/administration & dosage, Quinolones/administration & dosage, Randomized Controlled Trial, Combination, Drug Therapy, Combination, Female, medicine.drug, medicine.medical_specialty, Adolescent, Research Support, Article, Benzodioxoles/administration & dosage, Sweat/chemistry, N.I.H, 03 medical and health sciences, Phase III, Research Support, N.I.H., Extramural, Double-Blind Method, Drug Therapy, Internal medicine, Journal Article, medicine, Aminophenols/administration & dosage, Humans, Benzodioxoles, business.industry, Extramural, medicine.disease, Pyrazoles/administration & dosage, Clinical trial, Regimen, chemistry, biology.protein, Pyrazoles, Cystic Fibrosis Transmembrane Conductance Regulator/genetics, sense organs, Cystic Fibrosis/drug therapy, business
وصف الملف: application/pdf; text/plain
-
2
المؤلفون: Jeffrey I. Weitz, Martin H. Prins, Akos F. Pap, Alexander T. Cohen, Peter Verhamme, Philip S. Wells, Jan Beyer-Westendorf, Anthonie W. A. Lensing, Rodney Hughes, Paolo Prandoni, Saskia Middeldorp, Mila Trajanovic, Roopen Arya, Nils Kucher, Henri Bounameaux
المساهمون: ACS - Pulmonary hypertension & thrombosis, Vascular Medicine, MUMC+: KIO Kemta (9), RS: CAPHRI - R5 - Optimising Patient Care, Epidemiologie, University of Zurich, Beyer-Westendorf, Jan
المصدر: Thrombosis research, 149, 29-37. Elsevier Limited
Thrombosis Research, 149, 29-37. Elsevier Science
Thrombosis Research, Vol. 149 (2017) pp. 29-37
Beyer-Westendorf, J, Lensing, A W A, Arya, R, Bounameaux, H, Cohen, A T, Wells, P S, Middeldorp, S, Verhamme, P, Hughes, R, Kucher, N, Pap, A F, Trajanovic, M, Prins, M H, Prandoni, P & Weitz, J I 2016, ' Choosing wisely: The impact of patient selection on efficacy and safety outcomes in the EINSTEIN-DVT/PE and AMPLIFY trials ', Thrombosis Research . https://doi.org/10.1016/j.thromres.2016.11.014مصطلحات موضوعية: Male, 2720 Hematology, 030204 cardiovascular system & hematology, law.invention, Rivaroxaban/administration & dosage/adverse effects/therapeutic use, Cohort Studies, DOUBLE-BLIND, 0302 clinical medicine, Randomized controlled trial, law, Hemorrhage/chemically induced, 030212 general & internal medicine, 610 Medicine & health, anticoagulation, rivaroxaban, ORAL ANTICOAGULANTS, ddc:616, DABIGATRAN, Pyridones/administration & dosage/adverse effects/therapeutic use, Hematology, Middle Aged, OPEN-LABEL, CANCER, Treatment Outcome, Cohort, Apixaban, Female, medicine.drug, Cohort study, Adult, medicine.medical_specialty, Pyridones, RANDOMIZED CONTROLLED-TRIALS, Factor Xa Inhibitors/administration & dosage/adverse effects/therapeutic use, venous thromboembolism, apixaban, Hemorrhage, Thrombophilia, Pyrazoles/administration & dosage/adverse effects/therapeutic use, 03 medical and health sciences, VITAMIN-K ANTAGONISTS, Internal medicine, medicine, Humans, cardiovascular diseases, METAANALYSIS, Aged, Rivaroxaban, business.industry, Patient Selection, 10031 Clinic for Angiology, RIVAROXABAN, medicine.disease, Confidence interval, Surgery, Relative risk, Pyrazoles, ACUTE VENOUS THROMBOEMBOLISM, business, Venous Thromboembolism/drug therapy, Factor Xa Inhibitors
وصف الملف: application/pdf
-
3
المؤلفون: Gregory Y.H. Lip
المصدر: Lip, G Y H 2019, ' The safety of NOACs in atrial fibrillation patient subgroups : A narrative review ', International Journal of Clinical Practice, vol. 73, no. 2, e13285 . https://doi.org/10.1111/ijcp.13285
INTERNATIONAL JOURNAL OF CLINICAL PRACTICEمصطلحات موضوعية: Stroke/etiology, medicine.medical_specialty, Pyridines, Pyridones, Rivaroxaban/administration & dosage, Patient subgroups, MEDLINE, Administration, Oral, Hemorrhage, 030204 cardiovascular system & hematology, Warfarin/adverse effects, 03 medical and health sciences, 0302 clinical medicine, Rivaroxaban, Risk Factors, Thiazoles/administration & dosage, Hemorrhage/chemically induced, Atrial Fibrillation, medicine, Humans, Dabigatran/administration & dosage, cardiovascular diseases, 030212 general & internal medicine, Pyridines/administration & dosage, Intensive care medicine, Stroke, Anticoagulants/administration & dosage, Pyridones/administration & dosage, business.industry, Warfarin, Age Factors, Anticoagulants, Atrial fibrillation, General Medicine, medicine.disease, Pyrazoles/administration & dosage, Dabigatran, Clinical trial, Thiazoles, Clinical Trials, Phase III as Topic, Pyrazoles, Narrative review, business, Atrial Fibrillation/complications, Major bleeding, medicine.drug
وصف الملف: application/pdf
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c31a03596faff0bfee86879256cde1c4
https://vbn.aau.dk/ws/files/293589076/The_safety_of_NOACs_in_atrial_fibrillation_patient_subgroups_A_narrative_review.pdf -
4
المؤلفون: Loriot, Yohann, Necchi, Andrea, Park, Se Hoon, Garcia-Donas, Jesus, Huddart, Robert, Burgess, Earle, Fleming, Mark, Rezazadeh, Arash, Mellado, Begoña, Varlamov, Sergey, Joshi, Monika, Duran, Ignacio, Tagawa, Scott, Zakharia, Yousef, Zhong, Bob, Stuyckens, Kim, Santiago-Walker, Ademi, De Porre, Peter, O’Hagan, Anne, Avadhani, Anjali, Siefker-Radtke, Arlene, Houédé, Nadine
المساهمون: Loriot, Y, Necchi, A, Park, Sh, Garcia-Donas, J, Huddart, R, Burgess, E, Fleming, M, Rezazadeh, A, Mellado, B, Varlamov, S, Joshi, M, Duran, I, Tagawa, St, Zakharia, Y, Zhong, B, Stuyckens, K, Santiago-Walker, A, De Porre, P, O'Hagan, A, Avadhani, A, Siefker-Radtke, Ao, Département de médecine oncologique [Gustave Roussy], Institut Gustave Roussy (IGR), Fondazione IRCCS Istituto Nazionale dei Tumori, Samsung Medical Center Sungkyunkwan University School of Medicine, Institute Division of Hematology/Oncology, Centro Integral Oncologico Clara Campal, Academic Radiotherapy Unit, Institute of cancer research, The Levine Cancer Institute, Virginia Oncology Associates, University of Louisville, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Department of Scientific Information Analyses, Siberian Research Institute of Cheese-Making, Barnaul, Russia, Department of Veterinary and Biomedical Sciences, Penn State Cancer Institute, The Pennsylvania State University, 115 Henning Building, University Park, PA 16802, USA., Marqués de Valdecilla University Hospital [Santander], Weill Medical College of Cornell University [New York], Department of Pediatrics and Holden Comprehensive Cancer Center [Iowa City, USA], University of Iowa [Iowa City]-Carver College of Medicine, University of Iowa, Janssen Research & Development [Spring House, PA, USA], Janssen Pharmaceutica [Beerse], Institut de Recherche en Cancérologie de Montpellier (IRCM - U1194 Inserm - UM), CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)
المصدر: New England Journal of Medicine
New England Journal of Medicine, Massachusetts Medical Society, 2019, 381 (4), pp.338-348. ⟨10.1056/NEJMoa1817323⟩مصطلحات موضوعية: Adult, Urologic Neoplasms, Metastatic Urothelial Carcinoma, Antineoplastic Agents, [SDV.CAN]Life Sciences [q-bio]/Cancer, Kaplan-Meier Estimate, 030204 cardiovascular system & hematology, medicine.disease_cause, 03 medical and health sciences, 0302 clinical medicine, Immune system, Erdafitinib, Quinoxalines, Humans, MESH: Quinoxalines / administration & dosage, Receptors, Fibroblast Growth Factor / antagonists & inhibitors, Receptors, Fibroblast Growth Factor / genetics, Urologic Neoplasms / drug therapy, Medicine, 030212 general & internal medicine, Progression-free survival, Neoplasm Metastasis, Urothelium, Receptor, Protein Kinase Inhibitors, Aged, Aged, 80 and over, Mutation, MESH: Antineoplastic Agents / administration & dosage, Protein Kinase Inhibitors / administration & dosage, Pyrazoles / administration & dosage, business.industry, General Medicine, Middle Aged, Protein-Tyrosine Kinases, [SDV.SP]Life Sciences [q-bio]/Pharmaceutical sciences, Receptors, Fibroblast Growth Factor, Progression-Free Survival, 3. Good health, Treatment Outcome, Fibroblast growth factor receptor, Cancer research, Pyrazoles, business
-
5
المؤلفون: Elaine Kilgour, Marie Cullberg, Jean-Charles Soria, Michael F. Berger, David Ferry, Fabrice Andre, A. Nigel Brooks, Ronglai Shen, Paul K. Paik, Claire Rooney, Neil R. Smith, Donal Landers, Alastair Mathewson, Paul Frewer
المصدر: Paik, P K, Shen, R, Berger, M F, Ferry, D, Soria, J-C, Mathewson, A, Rooney, C, Smith, N R, Cullberg, M, Kilgour, E, Landers, D, Frewer, P, Brooks, N & André, F 2017, ' A Phase Ib Open-Label Multicenter Study of AZD4547 in Patients with Advanced Squamous Cell Lung Cancers ', Clinical cancer research : an official journal of the American Association for Cancer Research, vol. 23, no. 18, pp. 5366-5373 . https://doi.org/10.1158/1078-0432.CCR-17-0645
مصطلحات موضوعية: 0301 basic medicine, Oncology, Male, Cancer Research, Pathology, Lung Neoplasms, Piperazines, 0302 clinical medicine, Carcinoma, Squamous Cell/drug therapy, Gene duplication, Clinical endpoint, Medicine, Neoplasm Metastasis, Manchester Cancer Research Centre, Middle Aged, Antineoplastic Agents/administration & dosage, Treatment Outcome, Tolerability, 030220 oncology & carcinogenesis, Benzamides, Carcinoma, Squamous Cell, Female, Chromosomes, Human, Pair 8, medicine.medical_specialty, Antineoplastic Agents, Article, 03 medical and health sciences, Genetic Heterogeneity, Internal medicine, Carcinoma, Benzamides/administration & dosage, Humans, Receptor, Fibroblast Growth Factor, Type 1, Adverse effect, Lung Neoplasms/drug therapy, Aged, Neoplasm Staging, business.industry, Receptor, Fibroblast Growth Factor, Type 1/genetics, Gene Expression Profiling, ResearchInstitutes_Networks_Beacons/mcrc, Gene Amplification, Cancer, Piperazines/administration & dosage, Sequence Analysis, DNA, medicine.disease, Pyrazoles/administration & dosage, Gene expression profiling, stomatognathic diseases, 030104 developmental biology, Pharmacodynamics, Pyrazoles, Neoplasm Grading, business
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::990f2a483a46e22776bff83e60c537f8
https://research.manchester.ac.uk/en/publications/3279fad9-f754-4e8a-b3e0-f835a5a0b263 -
6
المؤلفون: Andrea Varga, Antoine Hollebecque, Rastilav Bahleda, Anas Gazzah, Christophe Massard, Sandrine Aspeslagh, Jean-Charles Soria, Anna Spreafico, Michele Reni, Kunwar Shailubhai
المساهمون: Medical Oncology
مصطلحات موضوعية: 0301 basic medicine, Oncology, Male, Cancer Research, Lung Neoplasms, Antimetabolites, Antineoplastic/administration & dosage, Carcinoma, Non-Small-Cell Lung/drug therapy, Toxicology, Deoxycytidine, Gastroenterology, 0302 clinical medicine, Carcinoma, Non-Small-Cell Lung, Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Pharmacology (medical), Drug Interactions, Middle Aged, Cyclin-Dependent Kinases, Treatment Outcome, Tolerability, 030220 oncology & carcinogenesis, Peritoneal mesothelioma, Female, medicine.drug, Antimetabolites, Antineoplastic, medicine.medical_specialty, Maximum Tolerated Dose, Neutropenia, Cyclin-Dependent Kinases/antagonists & inhibitors, 03 medical and health sciences, Refractory, Pharmacokinetics, Internal medicine, medicine, Humans, Lung Neoplasms/drug therapy, Deoxycytidine/administration & dosage, Aged, Pharmacology, business.industry, Antineoplastic Combined Chemotherapy Protocols/adverse effects, medicine.disease, Pyrazoles/administration & dosage, Gemcitabine, Quinazolines/administration & dosage, Neoplasms/drug therapy, Regimen, 030104 developmental biology, Drug Resistance, Neoplasm, Concomitant, Quinazolines, Pyrazoles, business
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::42306b90b467bedc036686d59e41b35d
https://hdl.handle.net/20.500.14017/91e1653b-3c7b-4d0b-abd1-66ca3def9be4 -
7
المصدر: Journal of the American Society of Nephrology, Vol. 28, No 7 (2017) pp. 2241-2248
مصطلحات موضوعية: Male, Time Factors, Pyridones, medicine.medical_treatment, 030232 urology & nephrology, Pyrazoles/administration & dosage/pharmacokinetics, Renal function, 030204 cardiovascular system & hematology, 03 medical and health sciences, 0302 clinical medicine, Pharmacokinetics, Renal Dialysis, Up Front Matters, Pyridones/administration & dosage/pharmacokinetics, Medicine, Humans, Dialysis, Factor Xa Inhibitors/administration & dosage/pharmacokinetics, ddc:617, business.industry, Warfarin, Atrial fibrillation, General Medicine, Middle Aged, medicine.disease, Nephrology, Anesthesia, Stroke prevention, Pyrazoles, Apixaban, Female, Hemodialysis, business, Factor Xa Inhibitors, medicine.drug
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::787f5e2dffc4793802d1df4d8cf67552
https://archive-ouverte.unige.ch/unige:99765 -
8
المؤلفون: Christian Torp-Pedersen, Jannik Langtved Pallisgaard, Emil L. Fosbøl, Caroline Sindet-Pedersen, Morten Lamberts, Jonas Bjerring Olesen, Kasper Gadsbøll, Gunnar Gislason, Laila Staerk, Gregory Y.H. Lip
المصدر: Staerk, L, Fosbøl, E L, Gadsbøll, K, Sindet-Pedersen, C, Pallisgaard, J L, Lamberts, M, Lip, G Y H, Torp-Pedersen, C, Gislason, G H & Olesen, J B 2016, ' Non-Vitamin K antagonist oral anticoagulation usage according to age among patients with atrial fibrillation : Temporal trends 2011–2015 in Denmark ', Scientific Reports, vol. 6, 31477 . https://doi.org/10.1038/srep31477
Staerk, L, Fosbøl, E L, Gadsbøll, K, Sindet-Pedersen, C, Pallisgaard, J L, Lamberts, M, Lip, G Y H, Torp-Pedersen, C, Gislason, G H & Olesen, J B 2016, ' Non-vitamin K antagonist oral anticoagulation usage according to age among patients with atrial fibrillation : Temporal trends 2011-2015 in Denmark ', Scientific Reports, vol. 6, 31477 . https://doi.org/10.1038/srep31477
Staerk, L, Fosbøl, E L, Gadsbøll, K, Sindet-Pedersen, C, Pallisgaard, J L, Lamberts, M, Lip, G Y H, Torp-Pedersen, C, Gislason, G H & Olesen, J B 2016, ' Non-vitamin K antagonist oral anticoagulation usage according to age among patients with atrial fibrillation : temporal trends 2011-2015 in Denmark ', Scientific Reports, vol. 6, 31477 . https://doi.org/10.1038/srep31477
Scientific Reportsمصطلحات موضوعية: Adult, Male, Pediatrics, medicine.medical_specialty, Pyridones, medicine.drug_class, Denmark, Rivaroxaban/administration & dosage, MEDLINE, Administration, Oral, 030204 cardiovascular system & hematology, Antithrombins, Article, Antithrombins/administration & dosage, 03 medical and health sciences, 0302 clinical medicine, Rivaroxaban, Atrial Fibrillation, Journal Article, medicine, Humans, Dabigatran/administration & dosage, 030212 general & internal medicine, Registries, Practice Patterns, Physicians', Oral anticoagulation, Aged, Aged, 80 and over, Multidisciplinary, Pyridones/administration & dosage, Practice patterns, business.industry, Atrial Fibrillation/drug therapy, Antagonist, Age Factors, Atrial fibrillation, Vitamin K antagonist, Middle Aged, medicine.disease, Pyrazoles/administration & dosage, Dabigatran, Pyrazoles, Female, business
وصف الملف: application/pdf
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d08e4355ea87ed415ccbee5c979235b5
https://findresearcher.sdu.dk:8443/ws/files/124238400/Non_Vitamin_K_antagonist_oral_anticoagulation_usage_according_to_age_among_patients_with_atrial_fibrillation.pdf -
9
المؤلفون: Fabrizio Montecucco, Laura Massobrio, Alberto Valbusa, Gian Marco Rosa
المصدر: Swiss Medical Weekly
Swiss Medical Weekly, Vol. 145 (2015) P. w14048مصطلحات موضوعية: medicine.medical_specialty, MEDLINE, Comorbidity, Pyridones/administration & dosage/pharmacology, Warfarin/adverse effects, Chronic subdural haematoma, Hematoma, Pyrazoles/administration & dosage/pharmacology, Chronic subdural hematoma, Humans, Medicine, Stroke/prevention & control, Aged, ddc:616, business.industry, Factor Xa Inhibitors/administration & dosage/pharmacology, General Medicine, Cardiac Ablation, medicine.disease, Surgery, Hematoma, Subdural, Chronic/drug therapy/surgery, Female, Apixaban, Anticoagulants/adverse effects, business, medicine.drug
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fff53235715abf6dae46197fd33f9334
https://doi.org/10.4414/smw.2015.14048 -
10
المؤلفون: Joel Miller, Antoine Hollebecque, Antoine Italiano, Karim A. Benhadji, Christophe Massard, Nadine Houede, Jean-Charles Soria, Ezra E.W. Cohen, Paul Westwood, Les H. Brail, William Bumgardner
المساهمون: Département d’Innovation Thérapeutique et essais précoces [Gustave Roussy] (DITEP), Institut Gustave Roussy (IGR), Oncologie digestive, Département de médecine oncologique [Gustave Roussy], Institut Gustave Roussy (IGR)-Institut Gustave Roussy (IGR), Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Institut Bergonié [Bordeaux], UNICANCER, Institut de recherche en cancérologie de Montpellier (IRCM - U896 Inserm - UM1), Université Montpellier 1 (UM1)-CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Département de radiothérapie [Gustave Roussy]
المصدر: European Journal of Cancer
European Journal of Cancer, Elsevier, 2014, 50, pp.876--84. ⟨10.1016/j.ejca.2013.12.006⟩مصطلحات موضوعية: Oncology, Male, Cancer Research, Time Factors, Pharmacology, Pyrazoles/administration & dosage/adverse effects/pharmacokinetics, 70-kDa/*antagonists & inhibitors/metabolism, Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Proto-Oncogene Proteins c-akt/metabolism, Medicine, Fatigue, Clotting factor, Signal Transducing/metabolism, Adaptor Proteins, Ribosomal Protein S6 Kinases, 70-kDa, Common Terminology Criteria for Adverse Events, Vomiting/chemically induced, Middle Aged, 3. Good health, Anorexia, Treatment Outcome, Area Under Curve, Fatigue/chemically induced, Vomiting, Diarrhea/chemically induced, Female, Erlotinib, medicine.symptom, Drug, medicine.drug, Adult, Diarrhea, medicine.medical_specialty, Nausea, Metabolic Clearance Rate, Quinazolines/administration & dosage/adverse effects, [SDV.CAN]Life Sciences [q-bio]/Cancer, Anorexia/chemically induced, Drug Administration Schedule, Dose-Response Relationship, Neoplasms/*drug therapy/metabolism/pathology, effects/pharmacokinetics/*therapeutic use, Erlotinib Hydrochloride, Pharmacokinetics, Internal medicine, Humans, effects/pharmacokinetics, Everolimus, Adverse effect, Protein Kinase Inhibitors/administration & dosage/adverse, Protein Kinase Inhibitors, Adaptor Proteins, Signal Transducing, Aged, Pyrimidines/administration & dosage/adverse effects/pharmacokinetics, Sirolimus, Dose-Response Relationship, Drug, business.industry, Ribosomal Protein S6 Kinases, Sirolimus/administration & dosage/adverse effects/analogs & derivatives, Pyrimidines, Antineoplastic Combined Chemotherapy Protocols/adverse, Quinazolines, Pyrazoles, business, Proto-Oncogene Proteins c-akt